Autoantibodies to OxLDL fail to alter the clearance of injected OxLDL in apolipoprotein E-deficient mice

Journal of Lipid Research

Volumn 45, Issue 7, 2004, Pages 1347-1354

  Reardon, Catherine A ^a   Miller, Elizabeth R ^b   Blachowicz, Lydia ^a   Lukens, John ^a   Binder, Christoph J ^b   Witztum, Joseph L ^b   Getz, Godfrey S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

EO6 antibodies; Human low density lipoprotein; Oxidized low density lipoprotein; Oxidized phospholipid; Recombination activating gene deficient

Indexed keywords

ANTIBODY; APOLIPOPROTEIN B100; APOLIPOPROTEIN E; AUTOANTIBODY; COPPER; EPITOPE; OXIDIZED LOW DENSITY LIPOPROTEIN;

ARTICLE; B LYMPHOCYTE; FEMALE; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOCOMPETENCE; LIPID METABOLISM; MOUSE; NONHUMAN; OXIDATION; PLASMA CLEARANCE; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; APOLIPOPROTEIN B-100; APOLIPOPROTEINS B; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; AUTOANTIBODIES; EPITOPES; HUMANS; IMMUNOCOMPETENCE; LIPOPROTEINS, LDL; METABOLIC CLEARANCE RATE; MICE; MICE, KNOCKOUT;

EID: 3042613703     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: 10.1194/jlr.M400075-JLR200     Document Type: Article

References (35)

1. Pittman, R. C., T. E. Carew, A. D. Attie, J. L. Witztum, Y. Watanabe, and D. Steinberg. 1982. Receptor-dependent and receptor-independent degradation of low density lipoprotein in normal rabbits and in receptor-deficient mutant rabbits. J. Biol. Chem. 257: 7994-8000.
2. Goldstein, J. L., Y. K. Ho, S. K. Basu, and M. S. Brown. 1979. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc. Natl. Acad. Sci. USA. 76: 333-337.
3. Glass, C. K., and J. L. Witztum. 2001. Atherosclerosis: the road ahead. Cell. 104: 503-516.
4. Lusis, A.J. 2000. Atherosclerosis. Nature. 407: 233-241.
5. VanderLaan, P. A., C. A. Reardon, and G. S. Getz. 2004. Site specificity of atherosclerosis. Site-selective responses to atherosclerotic modulators. Arterioscler Thromb. Vasc. Biol. 24: 12-22.
6. Steinberg, D. 1997. Oxidative modification of LDL and atherogenesis. Circulation. 95: 1062-1071.
7. Salonen, J. T., D. Yla-Hertmala, R. Yamamoto, S. Butler, H. Korpela, R. Salonen, K. Nyyssonen, W. Palinski, and J. L. Witzum. 1992. Antoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 339: 883-887.
8. Virella, G., I. Virella, R. B. Leman, M. B. Pryor, and M. F. Lopes-Virella. 1993. Antioxidized low density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. Int. J. Clin. Lab. Res. 23: 95-101.
9. Palinski, W., V. Ord, A. S. Plump, J. L. Breslow, D. Steinberg, and J. L. Witztum. 1994. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis: demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Artetioscler. Thromb. 14: 605-616.
10. Palinski, W., R. K. Tangirala, E. Miller, S. G. Young, and J. L. Witztum. 1995. Increased autoantibody titers against epitopes of oxidized low density lipoprotein in LDL receptor-deficient mice with increased atherosclerosis. Artetioscler. Thromb. Vasc. Biol. 15: 1569-1576.
11. Palinski, W., E. Miller, and J. L. Witztum. 1995. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc. Natl. Acad. Sci. USA. 92: 821-825.
12. Ameli, S., A. Hultgardh-Nilsson, J. Regnstrom, F. Calara, J. Yano, B. Cercek, P. K. Shah, and J. Nilsson. 1996. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler. Thromb. Vasc. Biol. 16: 1074-1079.
13. Freigang, S., S. Hörkkö, E. Miller, J. L. Witztum, and W. Palinski. 1998. Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler. Thromb. Vasc. Biol. 18: 1972-1982.
14. George, J., A. Afek, B. Gilburd, H. Levkovitz, A. Shaish, I. Goldberg, Y. Kopolovic, G. Wick, Y. Shoenfeld, and D. Harats. 1998. Hyperimmunization of apoE-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis. 138: 147-152.
15. Zhou, X., G. Caligiuri, A. Hamsten, A. K. Lefvert, and G. K. Hansson. 2001. LDL immunization induces T cell dependent antibody formation and protection against atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21: 108-114.
16. Wiklund, O., J. L. Witztum, T. E. Carew, R. C. Pittman, R. L. Elam, and D. Steinberg. 1987. Turnover and tissue sites of degradation of glucosylated low density lipoprotein in normal and immunized rabbits. J. Lipid Res. 28: 1098-1109.
17. Dansky, H. M., S. A. Charlton, M. M. Harper, and J. D. Smith. 1997. T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. Proc. Natl. Acad. Sci. USA. 94: 4642-4646.
18. Reardon, C. A., L. Blachowicz, T. White, V. Cabana, Y. Wang, J. Lukens, J. Bluestone, and G. S. Getz. 2001. The effect of immune deficiency on lipoproteins and atherosclerosis in male apoprotein E deficient mice. Arterioscler. Thromb. Vasc. Biol. 21: 1011-1016.
19. Song, L., C. Leung, and C. Schindler. 2001. Lymphocytes are important in early atherosclerosis. J. Clin. Invest. 108: 251-259.
20. Palinski, W., S. Hörkkö, E. Miller, U. P. Steinbrecher, H. C. Powell, L. K. Curtiss, and J. L. Witztum. 1996. Cloning of monoclonal antibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J. Clin. Invest. 98: 800-814.
21. Shaw, P. X., S. Horkkö, M. K. Chang, L. K. Curtiss, W. Palinski, G.J. Silverman, and J. L. Witztum. 2000. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J. Clin. Invest. 105: 1731-1740.
22. Havel, R.J., H. A. Eder, and J. H. Bragdon. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 43: 1345-1353.
23. Lowry, O. H., N.J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275.
24. Hörkkö, S., E. Miller, D. W. Branch, W. Palinski, and J. L. Witztum. 1997. The epitopes for some and phospholipid antibodies are adducts of oxidized phospholipid and beta-2 glycoprotein 1 (and other proteins). Proc. Natl. Acad. Sci. USA. 94: 10356-10361.
25. Young, S. G., J. L. Witztum, D. C. Casal, L. K. Curtiss, and S. Bernstein. 1986. Conservation of the low density lipoprotein receptor-binding domain of apoprotein B. Demonstration by a new monoclonal antibody, MB47. Arteriosclerosis. 6: 178-188.
26. Zlot, C. H., L. M. Flynn, M. M. Verinant, E. Kim, M. Raabe, S. P. A. McCormick, P. Amtoroziak, L. M. McEvoy, and S. G. Young. 1999. Generation of monoclonal antibodies specific for mouse apolipoprotein B-100 in apolipoprotein B-48-only mice. J. Lipid Res. 40: 76-84.
27. Shih, D. M., Y-R. Xia, X-P. Wang, E. Miller, L. W. Castellani, G. Subbanagounder, H. Cheroutre, K. F. Faull, J. A. Berliner, J. L. Witztum, and A. J. Lusis. 2000. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J. Biol. Chem. 275: 17527-17535.
28. Woollett, L. A., Y. Osono, J. Herz, and J. M. Dietschy. 1995. Apolipoprotein E competitively inhibits receptor dependent low-density lipoprotein uptake by the liver but has no effect on cholesterol absorption or synthesis in the mouse. Proc. Natl. Acad. Sci. USA. 92: 12500-12504.
29. Sigari, F., C. Lee, J. L. Witztum, and P. D. Reaven. 1997. Fibroblasts that overexpress 15-lipoxygenase generate bioactive and minimally modified LDL. Arterioscler. Thromb. Vasc. Biol. 17: 3639-3645.
30. Shaw, P. X., C. S. Goodyear, M. K. Chang, J. L. Witztum, and G.J. SiIverman. 2003. The autoreactivity of anti-phosphorylcholine antibodies for atherosclerosis-associated neo-antigens and apoptotic cells. J. Immunol. 170: 6151-6157.
31. Hayek, T., J. Oiknine, J. G. Brook, and M. Aviram. 1994. Increased plasma and lipoprotein lipid peroxidation in apoE-deficient mice. Biochem. Biophys. Res. Commun. 20: 1567-1574.
32. Tangirala, R. K., D. Pratico, G. A. Fitzgerald, S. Chun, K. Tsukamoto, C. Mangeais, D. C. Usher, E. Pure, and D.J. Rader. 2001. Reduction of isoprostanes and regression of advanced atherosclerosis by apolipoprotein E. J. Biol. Chem. 276: 261-266.
33. Hörkkö, S., D. A. Bird, E. Miller, H. Itabe, N. Leitinger, G. Subbanagounder, J. A. Berliner, P. Friedmen, E. A. Dennis, L. K. Curtiss, W. Palinski, and J. L. Witztum. 1999. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid protein adducts inhibit macrophage uptake of oxidized low-density lipoprotein. J. Clin. Invest. 103: 117-128.
34. Boullier, A., D. A. Bird, M-K. Chang, E. A. Dennis, P. Friedman, K. Gillotte-Taylor, S. Hörkkö, W. Palinkski, O. Quehenberger, P. Shaw, D. Steinberg, V. Terpstra, and J. L. Witztum. 2001. Scavenger receptors, oxidized LDL, and atherosclerosis. Ann. N. Y. Acad. Sci. 947: 214-222.
35. Binder, C.J., S. Hörkkö, A. Dewan, M-K. Chang, E. P. Kieu, C. S. Goodyear, P. X. Shaw, W. Palinski, J. L. Witztum, and G. J. Silverman. 2003. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat. Med. 9: 736-743.